Obinutuzumab/Lenalidomide Combo Safe, Effective in Advanced Follicular Lymphoma
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide Consolidation Benefits CLL Patients Post Chemoimmunotherapy
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - August 2, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Does Frontline R2CHOP Reduce CNS Relapse Risk in DLBCL?
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide/Rituximab Combo Effective in Advanced FL
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma
A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
Leah LawrenceJun 3, 2018OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Celgene hunts deals to offset loss of Revlimid patent protection
Cancer treatment behind 63% of revenue could face competition from copycats in 2020 (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 8, 2018 Category: Pharmaceuticals Source Type: news

Immunotherapy Drugs Causing Vision Issues
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - March 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Off-label Lenalidomide Might Be Alternative to Thalidomide for Erythema Multiforme Off-label Lenalidomide Might Be Alternative to Thalidomide for Erythema Multiforme
Lenalidomide might be considered as off-label treatment for chronic erythema multiforme (EM) if the adverse effects of thalidomide are not acceptable, according to French researchers.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2018 Category: Allergy & Immunology Tags: Pharmacist News Source Type: news

Celgene to buy Juno for $9 billion to boost cancer pipeline
(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Celgene diversifies portfolio with purchase of Juno Therapeutics
Celgene Corp. has agreed to acquire Juno Therapeutics Inc. for about $9 billion, or $87 a share. The deal bolsters Celgene’s portfolio of blood-cancer drugs. The announcement comes on the heels of a report that the two companies were finalizing a deal, per The Wall Street Journal. Summit, New Jersey-based Celgene has been trying to diversify its portfolio to help offset losses it would s uffer if one of its drugs, Revlimid, loses patent protection in the U.S. This particular deal will add a… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 22, 2018 Category: Health Management Authors: Anthony Noto Source Type: news

Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early Use of KYPROLIS at First Relapse THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent ver...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib)...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Response to Lenalidomide Often Suboptimal in MDS/MPN - RS - T
Hematological responses seen in three patients with MDS/MPN - RS - T, but the responses not durable (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 1, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Lenalidomide Boosts Overall Survival After Stem Cell Tx (CME/CE)
(MedPage Today) -- Now considered a standard of care for multiple myeloma patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2017 Category: Hematology Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news

Survival Benefit in Myeloma With Lenalidomide Maintenance After Transplant
Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo. (Source: CancerNetwork)
Source: CancerNetwork - August 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Roswell Park-Led Analysis Shows Survival Benefit of Lenalidomide...
New research analysis published in JCO definitively shows an overall survival benefit from ongoing treatment with lenalidomide for patients with multiple myeloma who have already received bone marrow...(PRWeb August 15, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14605233.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 15, 2017 Category: Pharmaceuticals Source Type: news

Maintenance Lenalidomide Improves PFS in DLBCL (CME/CE)
(MedPage Today) -- No difference in OS compared with placebo after a median follow-up of 52 months (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 4, 2017 Category: Primary Care Source Type: news

Revlimid drives Celgene profit beat; raises EPS forecast
(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Celgene to Pay $280 Million to Settle Off-label Marketing Case Celgene to Pay $280 Million to Settle Off-label Marketing Case
The U.S. Justice Department said on Tuesday that Celgene Corp had agreed to pay $280 million to settle a lawsuit that accused the company of promoting its cancer drugs Revlimid and Thalomid for off-label uses.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers. (Source: NYT Health)
Source: NYT Health - July 26, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Suits and Litigation (Civil) Thalidomide (Drug) Celgene Corporation Whistle-Blowers Cancer Food and Drug Administration Source Type: news

FDA Halts Pembrolizumab Trials in Multiple Myeloma
The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint ...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide-Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

DARZALEX ® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
DARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor) (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 17, 2017 Category: Pharmaceuticals Source Type: news

Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma News Source Type: news

Janssen reports positive results from two Phase III combination trials of Darzalex
Janssen Research& Development has reported positive results from the updated Phase III CASTOR and POLLUX clinical trials of Darzalex (daratumumab) combined with bortezomib and dexamethasone or lenalidomide and dexamethasone to treat patients with mu … (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

Outcomes and Impact of Age on Therapy for Multiple Myeloma Outcomes and Impact of Age on Therapy for Multiple Myeloma
Is lenalidomide with low-dose dexamethasone effective for stem-cell transplantation-ineligible patients of any age with newly diagnosed MM?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Maintenance Lenalidomide Delayed Progression After R-CHOP for DLBCL
Maintenance lenalidomide significantly prolonged progression-free survival in elderly patients with diffuse large B-cell lymphoma who responded to first-line R-CHOP. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

MUK Phase Ib trial to assess Reolysin + Imnovid / Revlimid combination to treat myeloma
Cancer charity Myeloma UK and biotechnolgy firm Oncolytics Biotech have commenced a Phase Ib MUK eleven trial of Reolysin (pelareorep) in combination with Imnovid (pomalidomide) or Revlimid (lenalidomide) to treat patients with relapsing myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 17, 2017 Category: Pharmaceuticals Source Type: news

Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma
CALGARY, March 16, 2017 -- (Healthcare Sales & Marketing Network) - Oncolytics Biotech® Inc. (Oncolytics or the Company) (ONC.TO) (ONCYF) today announced that cancer charity Myeloma UK launched MUK eleven, a first-of-its-kind immunotherapy trial that ... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, pelareorep, pomalidomide, Revlimid, myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 16, 2017 Category: Pharmaceuticals Source Type: news

Revlimid (Lenalidomide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 6, 2017 Category: Drugs & Pharmacology Source Type: news

' DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma'DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma
The combination of daratumumab, lenalidomide and dexamethasone (DaraLenDex) appears to offer the best outcomes in patients with relapsed and/or refractory multiple myeloma (MM), according to a network meta-analysis involving 18 treatment options.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Maintenance Lenalidomide for Multiple Myeloma
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Lenalidomide Approved for Myeloma Maintenance After HSCT Lenalidomide Approved for Myeloma Maintenance After HSCT
Lenalidomide (Revlimid) gets the first-ever FDA approval for use in myeloma as a maintenance therapy after autologous stem cell transplant.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Expands Indication for Revlimid (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)
SUMMIT, N.J.--(BUSINESS WIRE) February 22,2017 -- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2017 Category: Drugs & Pharmacology Source Type: news

Bortezomib Triplet Improves Outcomes in Newly Diagnosed Multiple Myeloma
Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Frontline Triplet With Bortezomib: New Standard in Myeloma? Frontline Triplet With Bortezomib: New Standard in Myeloma?
Bortezomib added to lenalidomide plus dexamethasone significantly increased both progression-free and overall survival in multiple myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lenalidomide Maintenance Improves Survival in Poor Prognosis DLBCL
Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2016 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news

Myeloma XI ’s Phase III trial result shows increase in myeloma patient remission
Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news